Enimmune corporation

Enimmune corporation

TTPEX:6564
15.10
TWD
+0.10
(+0.67%)
1.15BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.05
0.04
0.03
0.04
0.43
1.82
2.95
0.66
0.56
0.67
- -
Basic EPS, GAAP
-1.6
-0.83
-2.37
-1.28
-1.39
-0.78
-3.88
-3.4
-2.2
-2.28
- -
Free Cash Flow per Basic Share
-1.74
-2.35
-2.02
-1.36
-2.09
-1.25
-3.14
-2.1
-2.02
-2.04
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
9.76
9
8.37
7.15
10.25
9.47
8.26
4.88
5.19
2.08
1.39
Tangible Book Value per Share
7.72
5.93
5.41
4.31
8.19
7.48
6.53
3.23
3.74
0.7
0.05
Basic Weighted Avg Shares
41
41
43
44
54
60
64
66
72
72
72
Sales/Revenue/Turnover
2
2
1
2
23
110
188
43
40
48
- -
Operating Margin (%)
-3,496.34
-2,212.29
-8,999.31
-3,696.81
-361.61
-53.36
-149.4
-559.4
-379.02
-387.64
- -
Depreciation Expense
3
3
5
6
7
9
8
8
8
9
- -
Net Income, GAAP
-66
-34
-101
-57
-74
-47
-248
-224
-158
-164
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-3,340.29
-2,016.18
-8,696.03
-2,913.84
-325.46
-43.02
-131.6
-514.42
-394.7
-341.01
- -
Working Capital
349
265
245
195
491
449
524
294
348
44
4
LT Debt
- -
- -
- -
- -
8
5
6
2
5
33
36
Total Equity
442
407
379
324
617
570
665
431
479
150
100
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-8.08
-25.64
-16.13
-15.83
-7.96
-44.49
-51.64
-45.27
-62.76
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
140
139
124
LT Borrowings
22
28
33
LT Finance Leases
6
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
72
72
72
Market Capitalization
1,113
1,484
1,152

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
379
318
267
Cash, Cash Equivalents & STI
289
247
193
Accounts Receivable, Net
10
13
15
Inventories
39
21
22
Total Current Liabilities
269
274
263
Payables & Accruals
- -
- -
- -
ST Debt
140
139
124
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-16.75%
-68.76%
Free Cash Flow
- -
22.09%
2.2%
Net Income, GAAP
- -
70.65%
4.32%
Sales/Revenue/Turnover
- -
77.45%
20.74%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
40
2025
- -
- -
48
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-2.2
2025
- -
- -
-2.28
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Che Wei Chang
Full Time Employees
27
Sector
Health technology
Industry
Biotechnology
Address
No. 76, Section 2 Taipei TPE Taiwan 106485
IPO Date
Sep 18, 2018
Business
Enimmune Corporation operates as a biotechnology company specializing in the research, development, production, and marketing of new drugs and vaccines. Its main products include vaccines targeting infectious diseases such as enterovirus 71 (EV71), Japanese encephalitis virus, EV71 plus CA16 bivalent vaccines, pneumococcal vaccines, and biological drugs including monoclonal antibodies. It also develops diagnostic products like the Speedy COVID-19 Ag Rapid Test for SARS-CoV-2 detection. The company undertakes clinical trials, new drug applications, and collaborates with research-based pharmaceutical firms to facilitate drug commercialization. Enimmune’s business model emphasizes strategic alliances within the ecosystem to efficiently bring new drugs to market, including licensing phased results to other manufacturers. Founded in 2014 and headquartered in Taichung City, Taiwan, it is a subsidiary initially established with backing from Adimmune Corporation and venture capital partners. Recent major developments include the launch of the EnVAX-A71 vaccine against enterovirus 71, which received market authorization in Taiwan in early 2023, and ongoing efforts to expand into the ASEAN market through strategic partnerships and clinical trials in Vietnam. Enimmune also secured Halal certification for its vaccine and signed a marketing and sales memorandum of understanding with Vietnam’s largest state-owned vaccine company, targeting protection for children across Asia with annual demand exceeding 20 million doses. The company continues to advance its portfolio with vaccine development for diseases such as norovirus, dengue fever, Middle East respiratory syndrome (MERS), and plans for a Japanese encephalitis vaccine based on cell culture technology, replacing traditional methods. Enimmune’s product offerings extend to biopharmaceutical agents, monoclonal antibodies, small molecule drugs, and innovative diagnostics, positioning it as a key player in Taiwan’s biopharmaceutical industry with a growing international footprint. Its operational strategy leverages high-capacity manufacturing and CDMO services from its parent and associated companies to sustain growth and expand global market reach.